Silence Therapeutics Plc - ADR logo

SLN

Silence Therapeutics Plc - ADR

$9.85

Earnings Summary

Revenue
$5.72Mn
Net Profits
$-7.68Mn
Net Profit Margins
-134.29%

Highlights

Revenue:

Silence Therapeutics Plc - ADR’s revenue jumped 82% since last year same period to $5.72Mn in the Q1 2022. On a quarterly growth basis, Silence Therapeutics Plc - ADR has generated 67.6% jump in its revenue since last 3-months.

Net Profits:

Silence Therapeutics Plc - ADR’s net profit jumped 8.74% since last year same period to $-7.68Mn in the Q1 2022. On a quarterly growth basis, Silence Therapeutics Plc - ADR has generated 18.55% jump in its net profits since last 3-months.

Net Profit Margins:

Silence Therapeutics Plc - ADR’s net profit margin jumped 49.86% since last year same period to -134.29% in the Q1 2022. On a quarterly growth basis, Silence Therapeutics Plc - ADR has generated 51.4% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Silence Therapeutics Plc - ADR post its latest quarter earnings

EPS Estimate Current Quarter
-0.15
EPS Estimate Current Year
-0.15

Highlights

EPS Estimate Current Quarter:

Silence Therapeutics Plc - ADR’s earning per share (EPS) estimates for the current quarter stand at -0.15 - a -Inf% fall from last quarter’s estimates.

EPS Estimate Current Year:

Silence Therapeutics Plc - ADR’s earning per share (EPS) estimates for the current year stand at -0.15.

Key Ratios

Key ratios of the Silence Therapeutics Plc - ADR post its Q1 2022 earnings

Earning Per Share (EPS)
-0.34
Return on Assets (ROA)
-0.31
Return on Equity (ROE)
-5.93
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Silence Therapeutics Plc - ADR’s earning per share (EPS) fell -118.88% since last year same period to -0.34 in the Q1 2022. This indicates that the Silence Therapeutics Plc - ADR has generated -118.88% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Silence Therapeutics Plc - ADR’s return on assets (ROA) stands at -0.31.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Silence Therapeutics Plc - ADR’s return on equity (ROE) stands at -5.93.

Dividend Per Share (DPS):

Silence Therapeutics Plc - ADR declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2021-09-30
-0.15
-0.15
1.91%

Company Information

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary messenger RNAi GOLD™ (GalNAc Oligonucleotide Discovery) Platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of

Organisation
Silence Therapeutics Plc - ADR
Headquarters
72 Hammersmith Road, London, United Kingdom
Employees
74
Industry
Health Technology
CEO
David Solomon